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Nitric oxide (NO) production impairment is involved in the onset and development of
hypertension. Although NO production impairment in spontaneously hypertensive rat
(SHR) has been reported in a variety of researches, the time course of this progressive
procedure, as well as its relationship with asymmetric dimethylarginine (ADMA) and
angiotensin II (Ang II), has not been quantified. The aim of this research is to establish a
mechanism-based disease progression model to assess Ang II and ADMA’s inhibition
of NO production in SHR’s disease progression with/without ramipril’s intervention.
SHR were randomly divided into three groups: one disease group (n = 8) and two
treatment groups (n = 8 for each group): standard treatment group (receiving ramipril
2mg/kg∗day) and intensive treatment group (receiving ramipril 10mg/kg∗day). ADMA,
Ang II, NO, and SBP were determined weekly. Intensive treatment with ramipril was
found to have no further attenuation of plasma NO and ADMA than standard treatment
beyond its significantly stronger antihypertensive effects. Four linked turnover models
were developed to characterize the profiles of ADMA, Ang II, NO, and SBP during
hypertensive disease progression with/without ramipril intervention. Our model described
Ang II and ADMA’s contribution to NO production impairment and their responses
to ramipril treatment throughout the disease progression in SHR. Model simulations
suggested that Ang II affected NO production mainly through inhibiting ADMA elimination
rather than affecting nitric oxide synthase (NOS) directly.
Keywords: angiotensin II, asymmetric dimethylarginine, disease progression modeling, hypertension, intensive
blood-pressure control, nitric oxide, spontaneously hypertensive rat
INTRODUCTION
Hypertension is a serious chronic disease that causes mortality and morbidity worldwide. A variety
of pathophysiological mechanisms are involved in the genesis and development of hypertension
(e.g., the activation of renin angiotensin system (RAS), impairment of nitric oxide synthase (NOS),
oxidative stress, etc.; Hamza and Dyck, 2014). In hypertensive patients (Schulz et al., 2011) and rats
(Landmesser et al., 2002; Mollnau et al., 2002), nitric oxide (NO) molecules are easily diminished
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by angiotensin II (Ang II) mediated over production of
reactive oxygen species (ROS), leading to a reduction of NO
bioavailability and endothelial dysfunction. Besides, enhanced
ROS could also reduce the activity of NOS through oxidizing
tetrahydrobiopterin (BH4), the cofactor of NOS, causing NOS
impairment and convert NOS to superoxide generators, thus
creating a vicious cycle (Baylis, 2012; Roe and Ren, 2012; Su,
2015). Although the end products of NO, nitrite and nitrate,
could not reflect NO bioavailability, plasma nitrite, and nitrate
together (NOx) has been widely used as an index of NO
formation and break down, reflecting NOS activity indirectly
(Zeballos et al., 1995; Jungersten et al., 1996). In addition, it is
also suggested that urinary NOx could not be used as a truly
quantitative indicator of NO production (Baylis and Vallance,
1998), since NO might also be excreted through expired air or
as other end products. Therefore, plasma NOx was selected to be
the indicator of NO production in this work. On the other hand,
asymmetric dimethyl arginine (ADMA) plays an important role
in bridging Ang II and NO. Elevated plasma ADMA level has
been widely reported in hypertensive patients (Surdacki et al.,
1999) and in SHR (Ghiadoni et al., 2007; Tain et al., 2011).
According to previous studies, the major removal of ADMA
is provided with dimethylarginine dimethylaminohydrolase
(DDAH; Baylis, 2012). Hence, the activity of DDAH would affect
the level of ADMA predominantly. As shown in Figure 1, the
activity of both isoforms of DDAH suffers from an intensive
inhibition by Ang II-mediated ROS generation (Palm et al., 2007;
Baylis, 2012). Since DDAH provides the majority of ADMA
removal (Baylis, 2012), inhibition of DDAH activity would lead
to accumulation of ADMA in vivo, which subsequently affects
the activity of NOS. Since these markers are closely related to
each other and contribute greatly to hypertension, assessing the
longitudinal time course of these markers might provide a better
understanding of NO production impairment in hypertension
disease progression of SHR.
The idea ofmodeling disease progression has been widely used
in chronic diseases, for example diabetes (Cao et al., 2011; Gao
et al., 2011), Parkinson’s disease (Vu et al., 2012), Alzheimer’s
disease (Zhou et al., 2013), and hypertension (Zhou et al., 2012).
Describing disease progression with responses to treatment in
a quantitative way makes predicting clinical outcome events
possible, which is especially essential in long-term progressive
diseases with poor prognosis (Holford, 2015). On the other
hand, model-based evaluation of disease progression provides
insight into the mechanism as well as evaluation of drug effect
on disease progression (Mould et al., 2007). In a previous
study carried out with Zhou et al., a disease progression model
was established for capturing the counter-balance relationship
between Ang II and Ang-(1-7) in SHR (Zhou et al., 2012). The
model satisfyingly described the two peptides’ counter regulatory
effects on blood pressure. In this paper, we aimed to offer a
Abbreviations: ADMA, asymmetric dimethylarginine; Ang II, angiotensin II;
DDAH, dimethylarginine dimethylaminohydrolase; GK rat, Goto-Kakizaki rat;
NO, nitric oxide; NOS, nitric oxide synthase; RAS, renin-angiotensin system;
ROS, reactive oxygen species; SBP, systolic blood pressure; SHR, spontaneously
hypertensive rat.
FIGURE 1 | Schematic diagram showing the mechanisms of Ang II
affecting nitric oxide system. Directly, Ang II-activated generation of free
radicals inhibits the activity of NOS directly. Indirectly, the activity of DDAH is
restricted by overproduced free radicals induced by Ang II, which leads to the
accumulation of ADMA. Elevated level of ADMA inhibits the activity of NOS
directly. The locations of simulated blockade are marked with corresponding
disease factors (IN_NOS, OX_DDAH, and OX_NOS) beside.
better understanding of Ang II and ADMA’s contributions to NO
production impairment in disease progression of SHR, with our
proposed model.
Ramipril, an ACE (angiotensin converting enzyme)
inhibitor, has been demonstrated to show cardiovascular
protection in SHR beyond antihypertensive action (Linz
et al., 1995; Gohlke et al., 1996). In addition, ramipril was
also reported to ameliorate endothelial dysfunction, restore
NOS impairment, and improve oxidative stress (Linz et al.,
2003; Yilmaz et al., 2007). Therefore, ramipril was selected
as a tool for modeling and validation, in order to gain more
information about the relationship between elevated plasma Ang
II level and NO production impairment. Two different doses
were set up to investigate whether intensive treatment with
ramipril could have more attenuation of NO production
impairment dependently of intensified blood pressure
control.
MATERIALS AND METHODS
Animals
Twenty-four 4-week-old male spontaneously hypertensive rats
were purchased from Vital River Laboratory Animal Technology
Co., Ltd. (Beijing, China). All rats were raised in 12-h light/12-
h dark cycle environment and had free access to water and
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food. This study was approved by Ethics Committee for Animal
Experimentation of China Pharmaceutical University. All efforts
were made to minimize animal suffering.
Materials
Ramipril was supplied by Kunshan Rotam Reddy Pharmaceutical
Co., Ltd. (Kunshan, China). Systolic blood pressure
was measured with ALC-NIBP (tail-cuff method) from
ALCBIO (Shanghai, China). Iodine [125I] Angiotensin II
Radioimmunoassay Kit was obtained from Beijing North
Institute of Biological Technology (Beijing, China).
Experimental Design
All rats were acclimatized for 1 week. From the age of 5 week,
24 SHR were randomly assigned to three groups: one disease
group and two ramipril treatment groups: standard treatment
group (receiving ramipril 2mg/kg/day) and intensive treatment
group (receiving ramipril 10mg/kg/day). Rats in two treatment
groups were given ramipril by gavage at 9:00 AM every day
from 18 to 21-week-age. SBP were measured weekly. Six hundred
microliter of blood sample was collected via tail vein once a
week with collection time fixed at 2:00 PM, blood samples
were anticoagulated with EDTA and centrifuged at 4000 g for
15min immediately. Plasma samples were aliquoted and stored at
−80◦Cuntil analysis. At the age of 21 week, all rats were sacrificed
by cervical dislocation.
Blood Pressure Measurement
The protocol for blood pressure measurement was designed
based on the method introduced in the works of Whitesall et al.
(2004) and Kubota et al. (2006). During the first week, all rats
were acclimated to restraint, tail-cuff inflation, and heating. Rats
were placed in plastic restrainers with heating pad remaining
at 33∼34◦C. The instrument (ALC-NIBP, ALCBIO; Shanghai,
China) automatically takes ten 30-s measurements. The values
of systolic blood pressure were recorded when more than five
consecutive stable readings were available. The highest and
lowest readings were discarded, and the remaining readings were
averaged for one data point.
ADMA, NO, and Ang II Assays
Plasma asymmetric dimethylarginine (ADMA) was measured
using an HPLC-MS/MS method introduced by He (He et al.,
2013). Plasma nitric oxide (NO) is determined by measuring
the stable end products, nitrite and nitrate, which is described
in the work of Moshage (Moshage et al., 1995). Plasma
angiotensin II (Ang II) was measured using radioimmunoassay
with commercial kit obtained from Beijing North Institute of
Biological Technology (Beijing, China).
Disease Progression Model
The general structure of the disease progression model is
shown in Figure 2. Basically, the model was composed with
three components: one defined the natural disease progression
in SHR without treatment as disease model; two of which
described ameliorated hypertensive disease progression with two
different doses of ramipril intervention as treatment model.
Four turnovers were applied for describing the dynamics of
FIGURE 2 | Model structure defining the interactions between ADMA,
Ang II, NO, and SBP during hypertension progression. Symbols and
parameters are defined under Materials and Methods and in Table 1. Lines
with arrows indicate conversion to or turnover of the indicated factors. Dashed
lines ending in closed circles indicate an action is exerted by the connected
factors. Solid bars indicate inhibiting effects, open bars indicate stimulating
effects.
plasma Ang II, plasma ADMA, plasma NO, and SBP, which are
represented by the following four equations:
dCANG
dt
= kin_ANG
(
1/(EIRAMI · exp(DOSE))
)
− kout_ANG · CANG · (1+ ESANG · CANG) (1)
dCADMA
dt
= kin_ADMA − kout_ADMA
·CADMA (1− IAANG [m] · CANG) (2)
dCNO
dt
= kin_NO (1− INADMA [n] · CADMA − INANG [o]
·CANG + ESSBP · CSBP)− kout_NO · CNO (3)
dSBP
dt
= kin_SBP
(
1+ ESANG
[
p
]
· CANG
)
− kout_SBP
·(1+ ESNO
[
q
]
) · SBP (4)
In which, CANG, CADMA, CNO, and SBP indicate plasma Ang
II, ADMA, NO concentration, and SBP level, respectively. In
this model, plasma Ang II was the marker that triggers the
cascade of downstream reactions. Plasma Ang II is assumed to
be formed at a zero-order constant rate (kin_ANG) and degraded
by the first-order constant rate (kout_ANG). The degradation of
Ang II is stimulated through a negative regulatory feedback
loop (ESANG; Zhou et al., 2012), which is characterized with a
linear model represented with ESANG. In two treatment groups,
plasma Ang II level is subjected to an inhibitory effect from
ramipril (EIRAMI), EIRAMI is a drug-specific parameter. The dose
of ramipril was indicated by parameter DOSE. DOSE was fixed at
0 when model was fitted in disease group, while at 2 or 10 in two
treatment groups, respectively. ADMA is synthesized by Protein
Arginine Methyltransferase (PRMT) and eliminated mainly
through dimethylarginine dimethylaminohydrolase (DDAH)
hydrolysis. Prior to occurrence of disease, plasma ADMA level
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TABLE 1 | Estimates and definition of parameters of the progression model in three groups.
Parameter (Unit) Definition Original dataset Bootstrap dataset
Mean ± SD %CV
Kin_ANG (pg/mL/week) Ang II production rate 122.0 115.4±9.3 8.09
Kout_ANG (1/week) Ang II output rate 2.111 1.98±0.16 8.369
Kin_ADMA (umol/L/week) ADMA production rate 0.1841 0.1855±0.012 6.26
Kout_ADMA (1/week) ADMA output rate 0.5854 0.5881±0.043 7.34
Kin_NO (umol/L/week) NO production rate 24.02 25.71±2.1 8.22
Kout_NO (1/week) NO output rate 0.5721 0.6033±0.046 7.64
Kin_SBP (1/week) SBP production rate 0.5075 0.5237±0.045 8.64
Kout_SBP (1/week) SBP output rate 0.003520 0.003638±0.00032 8.80
OX_DDAH (mL/week/pg) Disease factor: inhibition of DDAH activity through
oxidative effects
0.01668 0.01671±0.0014 8.58
IN_NOS (L/week/umolmol) Disease factor: inhibition of NOS activity by ADMA 0.7085 0.7331±0.053 7.30
OX_NOS (mL/week/pg) Disease factor: inhibition of NOS activity through
oxidative effects
0.001971 0.001982±2.1E−05 1.08
ESSBP (1/mmHg) Stimulation of NO production by SBP 0.005028 0.005007±3.8E−04 7.63
ESANG (1/mmHg) Negative feedback effect of Ang II 0.003453 0.003443±7.8E−05 2.26
VCON (mL/week/pg) Vasoconstriction effect of Ang II 0.8718 0.8975±0.048 5.30
VDIL (L/week/umolmol) Vasodilation effect of NO 0.8802 0.8691±0.065 7.52
EIRAMI Inhibitory effect from ramipril 1.114 1.128±0.088 7.84
kt1(1/week) Transduction rate constant 5.348 5.386±0.46 8.49
kt2(1/week) Transduction rate constant 0.3388 0.3493±0.018 5.27
kt3(1/week) Transduction rate constant 0.4441 0.471±0.047 9.94
kt4(1/week) Transduction rate constant 0.03067 0.02937±0.0069 23.5
kt5(1/week) Transduction rate constant 3.825 3.7957±0.081 2.14
m Number of transit compartments 1
n Number of transit compartments 1
o Number of transit compartments 2
p Number of transit compartments 1
q Number of transit compartments 1
remains at a relatively stable situation, which is represented
by a zero-order constant rate (kin_ADMA) for production and a
first-order constant rate (kout_ADMA) for elimination. According
to the previously mentioned mechanism, elimination of ADMA
is restrained with Ang II (IAANG[m]). IAANG[m] represents
the inhibitory effect that Ang II exerts on DDAH, where m
indicates the number of transit compartments that is applied to
simulate the inhibition of ADMA elimination by Ang II. A zero-
order constant rate kin_NO and a first-order constant rate kout_NO
are used to describe the generation and degradation of plasma
NO, respectively. In this system, activity of NOS is stimulated
by elevated blood pressure according to previous research
(Vaziri et al., 1998), which is simulated with a linear effect
represented by parameter ESSBP. The suppression of NOS activity
by plasma ADMA and plasma Ang II are described with two
transduction procedures INADMA[n] and INANG[o], respectively.
n and o indicate the number of the transit compartments that is
required for describing the effects. In this model, systolic blood
pressure is assumed to be input and output in zero-order rate
(kin_SBP) and first-order rate (kout_SBP), respectively, where Ang
II contributes to the climb of systolic blood pressure by causing
vasoconstriction, while NO eases systolic blood pressure through
vasodilation effect, which are represented with two separate series
of transit compartments ESANG[p] and ESNO[q].
Ang II Dynamics
At the beginning of the disease progression, plasma Ang II level
is described with the equation below:
CANG (0) =
kin_ANG
kout_ANG
(5)
In this model, Ang II accumulation is assumed to be spontaneous
and no other markers in this system would affect the procedure
of accumulation.
ADMA Dynamics
Plasma ADMA was assumed to be maintained at a steady
level before the initiation of the disease development, which is
reflected with the equation below:
CADMA (0) =
kin_ADMA
kout_ADMA
(6)
The turnover of plasma ADMA was mainly affected by the
activity of DDAH, which was inhibited by Ang II-induced
Frontiers in Physiology | www.frontiersin.org 4 November 2016 | Volume 7 | Article 555
Wang et al. Modeling Disease Progression in SHR
FIGURE 3 | Time course of plasma ADMA (A), Ang II (B), NO(C) and SBP (D) progression in the disease group (solid diamonds), standard treatment group
(2mg/kg) (solid triangles), and intensive treatment group (10mg/kg) (solid squares). Data are presented as mean ± SD. *p < 0.05 (one way ANOVA): Disease group
compares to standard treatment group (2mg/kg). #p < 0.05 (one way ANOVA): Disease group compares to intensive treatment group (10mg/kg). $p < 0.05 (one
way ANOVA): Standard treatment group (2mg/kg) compares to intensive treatment group (10mg/kg). The arrows point to the onset time of treatment.
ROS due to its high sensitivity to oxidative environment.
This inhibitory effect was simulated by a series of transit
compartments, which are represented by the following equations:
dIAANG(0)
dt
= OX_DDAH − kt1 · IAANG(0)
dIAANG(1)
dt
= kt1 · IAANG(0)− kt1 · IAANG(1)
. . .
dIAANG(m)
dt
= kt1 · IAANG(m− 1)− kt1 · IAANG(m) (7)
This transduction effect was assumed to be initiated by a disease
factor OX_DDAH, where m indicates the number of transit
compartments that were applied to describe the inhibition of
Ang II-mediated ROS on the elimination of ADMA; each transit
compartment was connected by a turnover rate constant kt1.
Different transit compartment numbers were evaluated to find
a number that sufficiently captured the stimulation.
NO Dynamics
The initial plasma NO level is represented with the following
equation:
CNO (0) =
kin_NO
kout_NO
(8)
During disease progression, the turnover of NO was mediated by
other three markers in this system. ADMA inhibits the synthesis
of NO directly by competitive binding to NOS. A series of transit
compartments was applied to describe this effect:
dINADMA(0)
dt
= IN_NOS− kt2 · INADMA(0)
dINADMA(1)
dt
= kt2 · INADMA(0)− kt2 · INADMA(1)
. . .
dINADMA(n)
dt
= kt2 · INADMA(n− 1)− kt2 · INADMA(n) (9)
This transduction effect was assumed to be initiated by a
disease factor IN_NOS, where n indicates the number of transit
compartments that were applied to simulate the inhibitory effect
of ADMA on the generation of NO; each transit compartment
was connected by a turnover rate constant kt2. Different transit
compartment numbers were evaluated to find a number that
sufficiently captured the inhibitory effect from ADMA on NOS.
Ang II-induced generation of ROS would sharply cut down
the activity of NOS. To mimic this effect, a series of transit
Frontiers in Physiology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 555
Wang et al. Modeling Disease Progression in SHR
FIGURE 4 | Predicted and observed values for ADMA (A), Ang II (B), NO (C), and SBP (D) in the disease group. All observations are reported as Mean ± SD
(open circles). The solid lines are the predicted values generated based on the original dataset.
compartments were utilized:
dINANG(0)
dt
= OX_NOS− kt3 · INANG(0)
dINANG(1)
dt
= kt3 · INANG(0)− kt3 · INANG(1)
. . .
dINANG(o)
dt
= kt3 · INANG(o− 1)− kt3 · INANG(o) (10)
This transduction effect was assumed to be initiated by a disease
factorOX_NOS, where INANG (o) indicates the number of transit
compartments that were applied to describe the inhibition from
Ang II-induced ROS on the generation of NO; each transit
compartment was connected by a turnover rate constant kt3.
Different transit compartment numbers were evaluated to find
a number that sufficiently captured the stimulation.
SBP Dynamics
SBP continues to climb during the growth of SHR till the age of
16–17 weeks. At the age of 5 weeks, the SBP of SHR is described
by the equation below:
CSBP (0) =
kin_SBP
kout_SBP
(11)
In the system we investigated, SBP was adjusted by Ang
II and NO in a manner of counterbalance. Ang II exerted
its pressor effect by causing vasoconstriction through binding
to AT1 receptors. On the contrary, the pressor effect was
being counterbalanced by vasodilator NO. This effect could be
described through two series of transit compartments, which are
represented by the following equations, respectively.
The first group of equations is proposed to represent
vasopressor effect:
dESANG(0)
dt
= VCON − kt4 · ESANG (0)
dESANG(1)
dt
= kt4 · ESANG(0)− kt4 · ESANG(1)
. . .
dESANG(p)
dt
= kt4 · ESANG(p− 1)− kt4 · ESANG(p) (12)
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FIGURE 5 | Predicted and observed values for ADMA (A), Ang II (B), NO (C), and SBP (D) in the standard treatment group. All observations are reported as
Mean ± SD (open circles). The solid lines are the predicted values generated based on the original dataset. The arrows point to the onset time of treatment.
VCON was assumed to be the initiative factor of vasoconstriction,
p indicates the number of transit compartments that were applied
to describe the vasoconstriction effect from Ang II; each transit
compartment was connected by a turnover rate constant kt4.
Different transit compartment numbers were evaluated to find
a number that sufficiently captured the stimulation.
The vasodilation effect of NO was represented with the
equations below:
dESNO(0)
dt
= VDIL− kt5 · ESNO(0)
dESNO(1)
dt
= kt5 · ESNO(0)− kt5 · ESNO(1)
. . .
dESNO(q)
dt
= kt5 · ESNO(q− 1)− kt5 · ESNO(q) (13)
The initiation of the vasodilation from NO was assumed
to be initiated by VDIL, q indicates the number of transit
compartments that were applied to describe the vasodilation
effect of NO; each transit compartment was connected by
a turnover rate constant kt5. Different transit compartment
numbers were evaluated to find a number that sufficiently
captured the stimulation.
Modeling and Simulation
The hypertensive disease progression combined with ramipril’s
effect was modeled using Phoenix 6.4 (CERTARA). The data
from total 24 rats in the disease group and treatment groups
were pooled together for baseline analysis in the initial 13
weeks. In the following 4 weeks, 8 rats in disease group were
contributed continually for baseline modeling, and 8 rats in
standard treatment group were used to estimate the drug effect
parameter EIRAMI . Eight rats in intensive treatment group
were used to validate the drug effect modeling. The validation
was performed by visual predictive check (VPC). Estimates of
parameters from the standard treatment group were used for the
performance of VPC. The baseline parameters were accordingly
fixed in drug effect estimation, assuming the baseline in treatment
groups did not change evidently from the disease group. The dose
of ramipril was represented with the parameterDOSE. DOSEwas
fixed at 0 in the disease group, while 2 and 10 in two treatment
groups, respectively. Model evaluation was performed using non-
parametric bootstrap analysis, introduced in previous research
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FIGURE 6 | Visual predictive check (VPC) of models for ADMA (A), Ang II (B), NO (C), and SBP (D) in the intensive treatment group (receiving ramipril
10mg/kg*day). Parameters (except DOSE) in standard treatment groups were fixed in the performance of VPC. The solid circles represent the observed data from
intensive treatment group (10mg/kg). The solid lines represent the 50th percentiles of the 1000 simulations. The dashed lines are the upper (95%) and lower (5%)
quantiles of the 1000 simulations. The arrows point to the onset time of treatment.
(Chen et al., 2009). Random draws of individual data from the
original dataset was repeated 100 times. The stability of the
final model was evaluated by comparing the model parameter
estimates from the average values of new datasets with that
obtained from the fit of the average values of original dataset.
Model simulations were conducted using mean estimates
obtained from the model to observe the effects on plasma NO
turnover throughout the disease progression from the three
disease factors:OX_DDAH, IN_NOS, andOX_NOS.OX_DDAH,
IN_NOS, or OX_NOS was fixed at zero in each simulation
respectively, which simulates the blockade of such disease
procedure.
RESULTS
Dynamics of SBP, Plasma Ang II, ADMA,
and NO
The time course of plasma angiotensin II (Ang II), asymmetric
dimethylarginine (ADMA), nitric oxide (NO) and systolic blood
pressure (SBP) variations during 5 to 21-week-age are shown in
Figure 3. In disease group, the change of SBP could be divided
into three stages. At the first stage, SBP climbed quickly from
under 140–180mmHg during the first 4–5 weeks. SBP then
grew to around 200mmHg at the age of 17 weeks in a more
slowly pace and remained at this level afterwards. Ramipril
showed significant antihypertensive effect from the data of two
treatment groups with a good dose-effect relationship. After 4
weeks’ therapy, SBP reached 146.8 ± 13.44mmHg in standard
treatment group and 127.4 ± 11.9mmHg in intensive treatment
group, respectively. Time course of plasma Ang II level in all
three groups of SHR went accordingly with the variation of
SBP. Higher dose of ramipril also showed a stronger effect
on plasma Ang II. Plasma ADMA, and NO did not vary
sharply compared to SBP and plasma Ang II. Nevertheless, the
accumulation of ADMA was observed in disease group. Plasma
NO was maintained at a relatively higher level before a drop
at the age of 12 weeks in all groups. Ramipril increased plasma
NO during the 4-week therapy. It is worth mentioning that
administration of 2mg/kg ramipril successfully dragged SBP
to 146.8 ± 13.44mmHg, reversed the accumulation of plasma
ADMA and increased plasma NO level, compared to disease
group. However, a higher dose (10mg/kg) of rampril with better
antihypertensive effect (dragging SBP to 127.4 ± 11.9mmHg)
failed to exert further attenuation of plasma ADMA and NO.
Disease Progression Model Analysis
The profiles of SBP, plasma Ang II, ADMA, and NO throughout
disease progression were reasonably fitted with our proposed
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FIGURE 7 | Conditional weighted residuals (CWRES) vs. predictions (PRED) for ADMA (A), Ang II (B), NO (C), and SBP (D) in the disease group.
model. The predicted values of SBP, plasma Ang II, ADMA,
and NO in disease group (Figure 4) and standard treatment
group (Figure 5) were fitted with the mean values from the
original data set. Parameter estimates and the optimized transit
compartment numbers are listed in Table 1. Parameter estimates
obtained from the fit of original mean data were within the
mean ± SD estimates of the bootstrap replicates. The result of
VPC for intensive treatment group has been demonstrated in
Figure 6. The observed values are well within the range between
5 and 95 percentiles of 1000 simulated values. The conditional
weighted residuals (CWRES) were randomly and homogenously
distributed around 0 (Figures 7, 8). The results suggested a
reasonable precision in the parameter estimates for the final
model.
Model Simulation
Based on mean parameter estimates of the model, simulations
were performed to predict the fraction of three disease factors
contributed to the turnover of plasma NO (Figure 9). Each
of the three disease factors (OX_DDAH, OX_NOS, IN_NOS)
was fixed at 0 for each simulation, assuming the blockade of
such disease procedure initiated by the corresponding disease
factor. The locations of simulated blockades are shown in
Figure 1. NO production was affected by three disease factors
with different extensions (Figure 9). The blockade of IN_NOS
showed the most significant improvement in NO production
(Figure 9, blue line). While blocking Ang II-mediated inhibition
of dimethylarginine dimethylaminohydrolase (DDAH) activity
(OX_DDAH) showed much milder effects on NO production
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FIGURE 8 | Conditional weighted residuals (CWRES) vs. predictions (PRED) for ADMA (A), Ang II (B), NO (C), and SBP (D) in the standard treatment group.
(Figure 9, purple line). Compared with them, blocking the direct
effect of Ang II-mediated oxidative stress on NOS (OX_NOS)
has the minimum improvement on NO production (Figure 9,
red line). Simulated data indicate that Ang II inhibited NO
production mainly through affecting ADMA hydrolysis rather
than suppressing NOS activity directly.
DISCUSSION
Nitric oxide (NO) is regarded as the controller of vascular
tone together with vasoconstriction factors, controlling blood
pressure. Besides, the abnormality of NO production will result
in endothelial dysfunction, leading to various cardiovascular
pathologies, like hypertension and atherosclerosis (Bryan, 2006;
Rochette et al., 2013). Therefore, modeling and simulating the
progression of NO production impairment could provide better
understanding of the disease progression in hypertension. On
the other hand, oxidative stress has been considered to cause
endothelial dysfunction in hypertensive subjects (Schulz et al.,
2011). Over produced ROS induced by angiotensin II (Ang II)
would suppress the activity of NO synthase (NOS) through
oxidizing tetrahydrobiopterin (BH4). Besides, dimethylarginine
dimethylaminohydrolase (DDAH), the metabolic enzyme of
asymmetric dimethylarginine (ADMA), is also sensitive to free
radicals (Palm et al., 2007). An enhancement of oxidative stress
in SHR has been demonstrated in a variety of researches. In the
work of Simao et al, renal H2O2, NADPH oxidase expression
as well as urinary thiobarbituric acid reactive substances
(TBARS) was found to increase in SHR (Simao et al., 2011).
Increased kidney TBARS was also found in SHR, indicating
enhanced oxidative stress (Chandran et al., 2014). Therefore, we
incorporated two series of transit compartments in our model,
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FIGURE 9 | Simulated plasma nitric oxide (NO) concentrations with the
blockade of affection from each of the three disease factors,
respectively. The predicted values of plasma NO in disease group are shown
in black line. The predicted values of plasma NO with blockade of disease
factor IN_NOS [inhibition of NO synthase (NOS) activity by asymmetric
dimethylarginine (ADMA)] are shown in blue line. The predicted values of
plasma NO with blockade of disease factor OX_DDAH (Ang II-mediated
inhibition on dimethylarginine dimethylaminohydrolase (DDAH) activity) are
shown in purple line. The predicted values of plasma NO with blockade of
disease factor OX_NOS (inhibition of NOS activity through oxidative effects) are
shown in red line. The definitions of disease factors are shown in Table 1 and
method.
simulating Ang II-mediated oxidative effects on DDAH and
NOS activities, triggered by two disease factors (OX_DDAH and
OX_NOS), respectively.
In the work of ND Vaziri et al. (1998), elevated plasma
and urinary NOx was observed in 12-week-age SHR, as well
as aorta NOS activity. However, in pre-hypertensive SHR (3-
week-old), plasma NOx was not significantly elevated compared
with Wistar Kyoto (WKY) rats. This might indicate that the
elevation of NO production in young SHR is progressive. It is also
mentioned that increased NO production during the early stage
of hypertension in SHR could not be maintained till the advanced
phase of the disease. With progressive endothelial dysfunction,
NO productionmay fall, leading to true NO deficiency in animals
with advanced hypertension. In other researches, impaired NO
productionwas also reported preceding the onset of hypertension
in SHR (Mokuno et al., 2001). Our results supported the finding
of ND Vaziri. In our work, NO production remained at a
higher level before the age of 12 weeks in SHR (Figure 3C),
indicating elevated NOS activity. Besides, the drop of NO
production initiated at the 12th week (Figure 3C) might indicate
the start of NOS impairment. Our model captured this procedure
(Figure 4C). Model simulations also revealed that three disease
factors contribute differently in NO production during disease
progression (Figure 9). Firstly, blocking IN_NOS showed the
most significant improvement in NO production, indicating
disease factor IN_NOS (inhibition of NOS activity by ADMA)
was the major contributor to the inhibition of NO production in
disease progression (Figure 9, blue line). Secondly, blocking Ang
II-mediated inhibition of DDAH activity (OX_DDAH) showed
much milder effects on NO production (Figure 9, purple line).
According to the mechanism (Figure 1), blockade of OX_DDAH
could reduce the accumulation of ADMA, decreasing ADMA
level. While blocking IN_NOS could directly intercept ADMA’s
inhibition onNOproduction. Since direct interception of ADMA
can obviously provide better improvement on NO production
than reducing ADMA accumulation, the results of simulation
is reasonable. Finally, blocking the direct effect of Ang II-
mediated oxidative stress on NOS (OX_NOS) has the minimum
improvement on NO production (Figure 9, red line). Compared
with the simulated values of blocking OX_DDAH, Ang II-
mediated oxidative stress might affect NO production mainly
through decreasing ADMA elimination instead of inhibiting
NOS activity directly. Blocking RAS was proved to protect renal
and vascular NOS, increasing NO production (Vaziri et al., 2002;
Zhou et al., 2008). In our work, ramipril increased the level of
plasma NO in rats from both treatment groups. However, this
effect was not enhanced with the increase of dose, which was also
reported by Pechánová (2007) and Christian Delles (Delles et al.,
2002). This might be explained that blocking RAS could only
suppress Ang II-mediated oxidative stress, but other sources of
ROS (e.g., xanthine oxidase, mitochondria and cyclooxygenase)
might not be attenuated by this action. As a result, the activities
of DDAH and NOS might not be better protected from ROS
despite a stronger antihypertensive action by a higher dose of
ramipril.
CONCLUSION
Our work revealed that intensive blood pressure control with
ramipril did not bring more benefits to attenuating plasma
ADMA and NO in SHR. The proposed model assessed Ang
II and ADMA’s contribution to NO production impairment
in SHR’s disease progression. The simulations suggested that
Ang II inhibited NO production mainly through affecting
ADMA elimination rather than directly affecting NOS activity in
hypertension progression of SHR.
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